Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 21, 2025npj VaccinesOpen Access

Immunogenicity and efficacy of homologous and heterologous NDV and MVA SARS-CoV-2 vaccines in mice and hamsters

View Full Paper
Ask AI
Bookmark
Share

Authors

PPPatricia PérezKJKaijun JiangIGIrene González-Domínguez

Discussion

Loading...

Member takes

Overview

Experiments demonstrated vaccines induce robust immunity, reducing viral replication and protecting the upper respiratory tract in mice and hamsters, suggesting strong potential against SARS-CoV-2.

Key Points

  • This research aims to evaluate the immunogenicity and efficacy of different vaccine regimens against SARS-CoV-2.
  • Evaluated homologous and heterologous prime/boost regimens in K18-hACE2 mice and Syrian hamsters
  • Used NDV-HXP-S (intranasal) and MVA-S(3P) (intramuscular) vectors encoding SARS-CoV-2 spike protein
  • Measured immune responses including serum IgGs and neutralizing antibodies, among others.
  • Vaccination protected against weight loss and reduced viral replication and lung pathology
  • Induced systemic and mucosal IgG and IgA responses against SARS-CoV-2
  • Demonstrated strong systemic T-cell responses with polyfunctional activity.

Cite This Study

Pérez et al. (2025) studied this question.

synapsesocial.com/papers/6924e3f2c0ce034ddc34f157https://doi.org/10.1038/s41541-025-01299-3
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Strong immunogenicity and protection against SARS-CoV-2 in hamsters induced by heterologous boost vaccination with an MVA-based COVID-19 vaccine candidate2025
  2. 2Intranasal vaccination with an NDV-vectored SARS-CoV-2 vaccine protects against Delta and Omicron challenges2024 · 10 citations
  3. 3Homologous MVA and heterologous DREP/MVA vaccine regimens induce robust and durable immune responses against SARS-CoV-22026 · 1 citations
  4. 4Intranasal Immunization with Live-Attenuated RSV-Vectored SARS-CoV-2 Vaccines Elicits Antigen-Specific Systemic and Mucosal Immunity and Protects Against Viral Challenge and Natural Infection2026
  5. 5Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium2024 · 11 citations